NCT05335941View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Urothelial CarcinomaMetastatic Cancer
Interventions
DRUG

Pemetrexed

Given by vein (IV)

DRUG

Zimberelimab

Given by vein (IV)

DRUG

Etrumadenant

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER